☆ 4.7 Meeting Abstract

Phase I results of CAM-H2: Safety profile and tumor targeting in patients.

JOURNAL OF CLINICAL ONCOLOGY (2018)

期刊

JOURNAL OF CLINICAL ONCOLOGY

卷 36, 期 15, 页码 -

出版社

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2018.36.15_suppl.e13017

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial

Alexander Spira, Michael S. Wertheim, Edward J. Kim, Benjamin Tan, Heinz-Josef Lenz, Petros Nikolinakos, Patricia L. Rich, Genevieve Jehl, Andreas Machl, Rena Ito, James L. Gulley, Scott Kopetz

Summary: A phase I study on bintrafusp alfa in heavily pretreated patients with colorectal cancer showed promising early signs of clinical efficacy and manageable safety profile.

ONCOLOGIST (2023)

添加到收藏夹

Article Oncology

Profile and outcome of cancer patients enrolled in contemporary phase I trials

Emily Alouani, Anas Gazzah, Sandrine Mercier, Ratislav Bahleda, Antoine Hollebecque, Jean-Marie Michot, Capucine Baldini, Samy Ammari, Stephane Champiat, Aurelien Marabelle, Sophie Postel-Vinay, Vincent Ribrag, Yohann Loriot, Santiago Ponce Aix, Linda Mahjoubi

Summary: This study provides an overview of the profile and outcomes of patients enrolled in phase I trials at Gustave Roussy. The results demonstrate that the outcomes of modern phase I trials have improved, indicating that they are now a valid and safe therapeutic option.

EUROPEAN JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

James H. Lewis, Hans Gelderblom, Michiel van de Sande, Silvia Stacchiotti, John H. Healey, William D. Tap, Andrew J. Wagner, Antonio Lopez Pousa, Mihaela Druta, Chia-Chi Lin, Hideo A. Baba, Youngsook Choi, Qiang Wang, Dale E. Shuster, Sebastian Bauer

Summary: In this study, the hepatic safety profile of pexidartinib in patients with TGCTs was evaluated. Most patients experienced reversible, low-grade isolated AST/ALT elevations, while a small percentage experienced serious mixed or cholestatic injury. Onset of hepatic adverse reactions was mainly in the first 2 months.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

A Phase I Trial to Determine the Safety and Tolerability of Autophagy Inhibition Using Chloroquine or Hydroxychloroquine in Combination With Carboplatin and Gemcitabine in Patients With Advanced Solid Tumors

Nagla Abdel Karim, Asad Ullah, Imran Ahmad, Elmustapha Bahassi, Olugbenga Olowokure, Ahmed Khaled, Harold Davis, John C. Morris

Summary: Autophagy is a process that helps cells survive during stressful conditions or attacks from chemotherapy or radiation. In this study, the safety and efficacy of combining chloroquine or hydroxychloroquine with carboplatin and gemcitabine in patients with advanced solid tumors were evaluated.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Food Science & Technology

Citrus aurantiifolia (Christm) Swingle: Biological potential and safety profile of essential oils from leaves and fruit peels

Patricia Weimer, Josue Guilherme Lisboa Moura, Vanessa Mossmann, Monica Luiza Immig, Juliana de Castilhos, Rochele Cassanta Rossi

Summary: This study evaluated the chemical composition, irritant potential, and antioxidant and cytotoxic activities of the essential oils extracted from leaves and fruit peels of C. aurantiifolia cultivated in southern Brazil. The leaf essential oil showed superior antioxidant potential and cytotoxicity compared to the fruit essential oil, and both oils exhibited better response in the HT-29 cell line. The effects of the oils were found to be dose-dependent, with no observed effect after dilution.

FOOD BIOSCIENCE (2021)

添加到收藏夹

Article Oncology

Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial

Lisa Zimmer, Elisabeth Livingstone, Angela Krackhardt, Erwin S. Schultz, Daniela Goppner, Chalid Assaf, Dietrich Trebing, Kai Stelter, Christine Windemuth-Kieselbach, Selma Ugurel, Dirk Schadendorf

Summary: The study presented phase I safety results of triplet therapy with PEM, ENC, and BIN in patients with advanced, BRAF(V600)-mutated melanoma, showing feasibility, safety, and clinically meaningful disease control.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan

Kunihiro Yamaoka, Yoshiya Tanaka, Hideto Kameda, Nasser Khan, Nobuhito Sasaki, Masayoshi Harigai, Yanna Song, Ying Zhang, Tsutomu Takeuchi

Summary: This study assessed the long-term safety of upadacitinib in Japanese patients with active RA compared to global clinical trial populations. The safety profile of upadacitinib was generally similar between Japanese and global RA populations, except for higher incidence rates of serious adverse events and infections, including herpes zoster, in the Japanese population.

DRUG SAFETY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

The mechanism of Hepatocyte-Targeting and safety profile of Phospholipid-Free small unilamellar vesicles

Nojoud A. L. Fayez, Roland Bottger, Jennifer Brown, Elham Rouhollahi, Shyh-Dar Li

Summary: This study elucidated the hepatocyte targeting mechanism of phospholipid-free small unilamellar vesicles (PFSUVs) and identified the key role of apolipoprotein AII (ApoA2). The study demonstrated that PFSUVs adsorbed plasma ApoA2 to their surface, which was recognized by the scavenger receptor B-1 (SR-B1) expressed on hepatocytes and internalized through clathrin-mediated endocytosis.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2022)

添加到收藏夹

Article Oncology

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors

Yuxiang Ma, Jinhui Xue, Yuanyuan Zhao, Yang Zhang, Yan Huang, Yunpeng Yang, Wenfeng Fang, Ye Guo, Qun Li, Xiaoxiao Ge, Jie Sun, Bangyong Zhang, Yuhan Zhang, Jinyuan Xiao, Li Zhang, Hongyun Zhao

Summary: KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4, showed promising antitumor efficacy and good tolerability in patients with advanced solid tumors, especially in those with nasopharyngeal carcinoma (NPC). The combination of CD8 and PD-L1 expression improved the prediction of KN046 response.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Article Food Science & Technology

Xanthohumol Microbiome and Signature in Healthy Adults (the XMaS Trial): Safety and Tolerability Results of a Phase I Triple-Masked, Placebo-Controlled Clinical Trial

Blake O. Langley, Jennifer Joan Ryan, Douglas Hanes, John Phipps, Emily Stack, Thomas O. Metz, J. Frederik Stevens, Ryan Bradley

Summary: A study found that 24 mg daily xanthohumol was safe and well-tolerated by healthy adults over an eight-week period, with no significant adverse reactions. There were no clinically relevant differences in physiological parameters and quality of life between the two groups during the trial.

MOLECULAR NUTRITION & FOOD RESEARCH (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Safety, Tolerability and Pharmacokinetics of Bencycloquidium Bromide, a Novel Inhaled Anticholinergic Bronchodilator, in Healthy Subjects: Results from Phase I Studies

Zhu Luo, Chao Hu, Yuanyuan Pan, Jia Miao, Ying Wang, Li Ding, Maozhi Liang

Summary: BCQB delivered via pMDI was well tolerated with favorable cardiovascular safety. The pharmacokinetic study suggested that sex did not affect BCQB metabolism, and dose adjustments based on sex are not anticipated in clinical use. The results support further clinical development in COPD patients.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)

添加到收藏夹

Article Oncology

The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts

Nancy Ann Oberheim-Bush, Wenyin Shi, Michael W. McDermott, Alexander Grote, Julia Stindl, Leonardo Lustgarten

Summary: This study evaluated the safety of TTFields therapy in patients with GBM and a VP shunt. Results showed that TTFields therapy was well tolerated and had a favorable safety profile in this population. There was no evidence of disruption to VP shunt effectiveness with TTFields therapy.

JOURNAL OF NEURO-ONCOLOGY (2022)

添加到收藏夹

Article Materials Science, Biomaterials

Molecularly imprinted polymer nanogels targeting the HAV motif in cadherins inhibit cell-cell adhesion and migration

Paulina X. Medina Rangel, Alejandra Mier, Elena Moroni, Franck Merlier, Levi A. Gheber, Razi Vago, Irene Maffucci, Bernadette Tse Sum Bui, Karsten Haupt

Summary: Cadherins are cell-surface proteins that play a crucial role in cell adhesion and are associated with cancer progression. This study proposes a synthetic antibody based on MIP-NGs that inhibits cell adhesion and migration, providing a potential alternative for cancer treatment.

JOURNAL OF MATERIALS CHEMISTRY B (2022)

添加到收藏夹

Article Oncology

Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

Qingsheng Xu, Kaiyuan Huang, Xiangqi Meng, Yuxiang Weng, Luyuan Zhang, Linghao Bu, Xiujue Zheng, Jinquan Cai, Renya Zhan, Qun Chen

Summary: The combination of anlotinib and temozolomide showed high efficacy and tolerability in treating recurrent GBM, with a good tumor response rate and disease control rate. This treatment regimen may contribute to an increase in progression-free survival and overall survival in patients with recurrent GBM.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Oncology

The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance

Longhao Zhang, Jingnan Xue, Nan Zhang, Yunchao Wang, Xu Yang, Shanshan Wang, Mingjian Piao, Kai Liu, Chengpei Zhu, Yanyu Wang, Jiashuo Chao, Cong Ning, Xinmu Zhang, Ziyu Xun, Yiran Li, Huishan Sun, Xiaobo Yang, Lijin Zhao, Haitao Zhao

Summary: This study evaluated the anti-tumor activity of adding bevacizumab as a means to reduce the blood vessels necessary for tumor growth in patients with advanced hepatocellular carcinoma (aHCC) who experienced disease progression after lenvatinib and immune checkpoint inhibitors (ICIs) treatment. The group that received bevacizumab had prolonged progression-free survival and a trend towards a benefit for overall survival duration compared to the control group. Bevacizumab could be a potential treatment option for aHCC patients after lenvatinib and PD-1/PD-L1 treatment.

AMERICAN JOURNAL OF CANCER RESEARCH (2023)

添加到收藏夹

Article Anesthesiology

Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria

Jo Nijs, Astrid Lahousse, Cesar Fontaine-de-las-Penas, Pascal Madeleine, Christel Fontaine, Tomohiko Nishigami, Christine Desmedt, Marian Vanhoeij, Kenza Mostaqim, Antonio I. Cuesta-Vargas, Eleni Kapreli, Paraskevi Bilika, Andrea Polli, Laurence Leysen, Omer Elma, Eva Roose, Emma Rheel, Sevilay Tumkaya Yilmaz, Liesbet De Baets, Eva Huyamans, Ali Turk, Ismail Saracoglu

Summary: Pain after cancer is often underestimated and undertreated. Precision medicine offers a way to classify patients into different subgroups based on their individual characteristics and tailor treatment accordingly. The application of precision medicine to post-cancer pain is an emerging issue, particularly in identifying and treating nociplastic pain. The 2021 IASP clinical criteria provide a framework for classifying and treating nociplastic pain in cancer patients, and the CANPPHE Network aims to implement and improve this approach through a diagnostic manual and case illustrations.

BRITISH JOURNAL OF ANAESTHESIA (2023)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Targeted a-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment

Thomas Ertveldt, Ahmet Krasniqi, Hannelore Ceuppens, Janik Puttemans, Yana Dekempeneer, Kevin De Jonghe, Wout de Mey, Quentin Lecocq, Yannick De Vlaeminck, Robin Maximilian Awad, Cleo Goyvaerts, Kim De Veirman, Alfred Morgenstern, Frank Bruchertseifer, Marleen Keyaerts, Nick Devoogdt, Matthias D'Huyvetter, Karine Breckpot

Summary: Targeted radionuclide therapy (TRT) using targeting moieties labeled with α-particle-emitting radionuclides (a-TRT) is an intensely investigated treatment approach. However, there is a lack of profound assessment of the immunomodulatory effect of a-TRT in literature.

JOURNAL OF NUCLEAR MEDICINE (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody

Maxime Nachit, Christopher Montemagno, Romain Clerc, Mitra Ahmadi, Francois Briand, Sandrine Bacot, Nick Devoogdt, Cindy Serdjebi, Catherine Ghezzi, Thierry Sulpice, Alexis Broisat, Isabelle A. Leclercq, Pascale Perret

Summary: In this study, researchers found that molecular imaging of VCAM-1 could be a non-invasive alternative to biopsy for detecting liver inflammation in chronic liver disease. By using radiolabeled anti-VCAM-1 nanobody and SPECT, they were able to quantify liver uptake and correlate it with histological inflammatory scores and molecular markers. The diagnostic power of this imaging tool to detect liver inflammation was excellent, suggesting its potential for clinical use.

NATURE COMMUNICATIONS (2023)

添加到收藏夹

Editorial Material Immunology

Imaging the immune response in inflammatory preclinical in vivo models

M. Erreni, G. Vande Velde, R. Weigert, N. Devoogdt

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Review Immunology

A few good reasons to use nanobodies for cancer treatment

Neema Ahishakiye Jumapili, Maida Zivalj, Romina Mora Barthelmess, Geert Raes, Timo W. M. De Groof, Nick Devoogdt, Benoit Stijlemans, Cecile Vincke, Jo A. Van Ginderachter

Summary: mAbs have limitations in their distribution and penetration in tumor microenvironment, as well as their ability to reach the brain. Nanobodies, being smaller in size, possess superior abilities in tumor penetration and infiltration into brain tumors. However, the rapid clearance of nanobodies from circulation may affect their suitability for therapy, although their noncovalent binding to albumin can help increase their serum half-life.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Current status and future expectations of nanobodies in oncology trials

Tessa De Pauw, Lynn De Mey, Jens M. Debacker, Geert Raes, Jo A. Van Ginderachter, Timo W. M. De Groof, Nick Devoogdt

Summary: Monoclonal antibodies have played a significant role in personalized medicine for cancer, but their size and complexity may hinder certain cancer diagnosis and therapy applications. Nanobodies, with their unique structure and pharmacological features, have shown promising potential as complementary tools for cancer diagnostics and therapeutics. This overview provides insights into nanobody-based diagnostics and therapeutics that have been tested in clinical trials and highlights upcoming preclinical developments.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2023)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)

Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, Denis Schallier, Sandrine Aspeslagh, Ilse Vaneycken, Geert Raes, Jo A. Van Ginderachter, Tony Lahoutte, Vicky Caveliers, Marleen Keyaerts

Summary: Macrophages play a vital role in the body, and anti-inflammatory macrophages targeting CD206 are involved in various diseases. This study evaluated the safety and biodistribution of a PET tracer targeting CD206 in human subjects, and found that the tracer was safe, rapidly cleared from the blood, and enabled high contrast imaging at 90 minutes after injection. Preliminary results showed higher tumor uptake in patients with disease progression.

JOURNAL OF NUCLEAR MEDICINE (2023)

添加到收藏夹

Article Oncology

Optimizing sexuality of young women with breast cancer: how can the breast clinic help?

Lara Vesentini, Laura Hoeylaerts, Roel Van Overmeire, Marian Vanhoeij, Sabien Bauwens, Johan Bilsen

Summary: This study explores how specialized breast clinics can help young women with their sexual health questions or problems by fulfilling their information and social support needs. The study finds that young women lack information on sexual issues and the information provided is not sufficiently tailored to them. The empathy and communication skills of healthcare providers play an important role in whether sexual issues can be discussed. Finally, the study suggests that more attention should be paid to the partner's well-being and the relationship.

SUPPORTIVE CARE IN CANCER (2023)

添加到收藏夹

Article Multidisciplinary Sciences

In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4+ T cells

Robin Maximilian Awad, Yannick De Vlaeminck, Fien Meeus, Thomas Ertveldt, Katty Zeven, Hannelore Ceuppens, Cleo Goyvaerts, Magali Verdonck, Gustavo Salguero, Geert Raes, Nick Devoogdt, Karine Breckpot

Summary: Blockade of the PD-1/PD-L1 immune checkpoint axis alleviates the inhibition of tumor-infiltrating lymphoid cells but weakly induces their expansion. Exogenous cytokines can further expand lymphoid cells and synergize with alpha PD-L1 therapy. Local delivery of cytokines and alpha PD-L1 therapeutics to immune cell-containing melanoma tumors effectively mediates anti-tumor activity and sensitizes the tumor microenvironment mainly through impacting NK cells.

SCIENTIFIC REPORTS (2023)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury

Raf Van Campenhout, Timo W. M. De Groof, Prashant Kadam, Brenda R. Kwak, Serge Muyldermans, Nick Devoogdt, Mathieu Vinken

Summary: This study successfully developed nanobody-based inhibitors targeting Pannexin1 channels, which showed affinity for both murine and human Pannexin1 proteins. These nanobodies were able to block the release of adenosine triphosphate and display anti-inflammatory effects in vitro, as well as in a relevant mouse model of acute liver disease. The findings suggest that these nanobodies hold promise as therapeutic agents for inflammatory disorders and provide novel tools for further research on the role of Pannexin1 channels in physiological and pathological processes.

JOURNAL OF NANOBIOTECHNOLOGY (2023)

添加到收藏夹

Article Immunology

Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT

Katty Zeven, Timo W. M. De Groof, Hannelore Ceuppens, Robin Maximilian Awad, Thomas Ertveldt, Wout de Mey, Fien Meeus, Geert Raes, Karine Breckpot, Nick Devoogdt

Summary: This study generated a panel of nanobodies targeting human or mouse TIGIT, and assessed their performance in vitro and in vivo. The nanobodies demonstrated excellent affinity and specific binding to TIGIT, and showed promising diagnostic potential for noninvasively imaging high TIGIT expression within the tumor. These findings hold promise for improving patient stratification and therapy response.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Surgery

Safe implementation of robotic right colectomy with intracorporeal anastomosis

E. Van Eetvelde, S. Violon, N. Poortmans, J. Stijns, M. Duinslaeger, M. Vanhoeij, R. Buyl, D. Jacobs-Tulleneers-Thevissen

Summary: This study demonstrates that robotic right colectomy with intracorporeal anastomosis can be safely implemented without increasing morbidity, although it requires a learning phase with longer procedure times compared to laparoscopy. The conversion rate from laparoscopy to robotic surgery is significantly reduced.

JOURNAL OF ROBOTIC SURGERY (2023)

添加到收藏夹

Meeting Abstract Oncology

Elevated LAG-3 expression in plasma cells and lymphoid subpopulations at distinct stages of multiple myeloma disease progression

Hatice Satilmis, Niels Vandewalle, Emma Verheye, Rong Fan, Elke De Bruyne, Eline Menu, Nick Devoogdt, Karin Vanderkerken, Karine Breckpot, Kim De Veirman

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.